Legacy Wealth Management LLC MS Trims Stock Position in Boston Scientific Corporation $BSX

Legacy Wealth Management LLC MS lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 13.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 43,165 shares of the medical equipment provider’s stock after selling 6,685 shares during the quarter. Boston Scientific makes up approximately 1.3% of Legacy Wealth Management LLC MS’s holdings, making the stock its 15th biggest holding. Legacy Wealth Management LLC MS’s holdings in Boston Scientific were worth $4,214,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. WD Rutherford LLC grew its position in shares of Boston Scientific by 39.0% during the 3rd quarter. WD Rutherford LLC now owns 22,849 shares of the medical equipment provider’s stock valued at $2,231,000 after buying an additional 6,414 shares during the last quarter. Strategic Planning Group LLC bought a new position in shares of Boston Scientific in the third quarter valued at approximately $4,396,000. Venturi Wealth Management LLC raised its holdings in shares of Boston Scientific by 1.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,035 shares of the medical equipment provider’s stock worth $882,000 after purchasing an additional 169 shares in the last quarter. Benjamin Edwards Inc. increased its holdings in shares of Boston Scientific by 3.8% in the third quarter. Benjamin Edwards Inc. now owns 18,426 shares of the medical equipment provider’s stock valued at $1,799,000 after buying an additional 670 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Boston Scientific by 251.9% during the 3rd quarter. SG Americas Securities LLC now owns 405,743 shares of the medical equipment provider’s stock valued at $39,613,000 after acquiring an additional 290,455 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Evercore ISI set a $112.00 price objective on Boston Scientific in a research note on Monday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Finally, Robert W. Baird upped their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $124.35.

Boston Scientific Trading Down 0.2%

BSX opened at $98.43 on Friday. The stock has a market capitalization of $145.92 billion, a PE ratio of 52.64, a PEG ratio of 1.75 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $97.64 and a two-hundred day moving average price of $100.81. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,095 shares of company stock valued at $9,305,450 in the last ninety days. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.